Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1935
mi
from 91732
Lithonia, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1935
mi
from 91732
Lithonia, GA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
664
mi
from 91732
Meridian, ID
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
664
mi
from 91732
Meridian, ID
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1663
mi
from 91732
Rockford, IL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1663
mi
from 91732
Rockford, IL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1853
mi
from 91732
Fort Wayne, IN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1853
mi
from 91732
Fort Wayne, IN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1806
mi
from 91732
Granger, IN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1806
mi
from 91732
Granger, IN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1495
mi
from 91732
Monroe, LA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1495
mi
from 91732
Monroe, LA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2614
mi
from 91732
Portland, ME
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2614
mi
from 91732
Portland, ME
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2185
mi
from 91732
Cumberland, MD
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2185
mi
from 91732
Cumberland, MD
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1975
mi
from 91732
Saint Clair Shores, MI
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1975
mi
from 91732
Saint Clair Shores, MI
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1609
mi
from 91732
Duluth, MN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1609
mi
from 91732
Duluth, MN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1676
mi
from 91732
Hattiesburg, MS
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1676
mi
from 91732
Hattiesburg, MS
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
208
mi
from 91732
Las Vegas, NV
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
208
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2420
mi
from 91732
Freehold, NJ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2420
mi
from 91732
Freehold, NJ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2385
mi
from 91732
Voorhees, NJ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2385
mi
from 91732
Voorhees, NJ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
660
mi
from 91732
Las Cruces, NM
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
660
mi
from 91732
Las Cruces, NM
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2437
mi
from 91732
Albany, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2437
mi
from 91732
Albany, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2448
mi
from 91732
Manhasset, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2448
mi
from 91732
Manhasset, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2461
mi
from 91732
Plainview, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2461
mi
from 91732
Plainview, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2451
mi
from 91732
Roslyn, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2451
mi
from 91732
Roslyn, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2194
mi
from 91732
Chapel Hill, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2214
mi
from 91732
Raleigh, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2214
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2263
mi
from 91732
Rocky Mount, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2263
mi
from 91732
Rocky Mount, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1938
mi
from 91732
Toledo, OH
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1938
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1164
mi
from 91732
Oklahoma City, OK
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2200
mi
from 91732
Duncansville, PA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2200
mi
from 91732
Duncansville, PA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2331
mi
from 91732
Wyomissing, PA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2331
mi
from 91732
Wyomissing, PA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1834
mi
from 91732
Cookeville, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1834
mi
from 91732
Cookeville, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1925
mi
from 91732
Knoxville, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1925
mi
from 91732
Knoxville, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1586
mi
from 91732
Memphis, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1586
mi
from 91732
Memphis, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1763
mi
from 91732
Nashville, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
922
mi
from 91732
Amarillo, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
922
mi
from 91732
Amarillo, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1213
mi
from 91732
Austin, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1213
mi
from 91732
Austin, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1378
mi
from 91732
Nassau Bay, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1378
mi
from 91732
Nassau Bay, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1208
mi
from 91732
Round Rock, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1208
mi
from 91732
Round Rock, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1288
mi
from 91732
Victoria, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1288
mi
from 91732
Victoria, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
527
mi
from 91732
Saint George, UT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
527
mi
from 91732
Saint George, UT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
939
mi
from 91732
Spokane, WA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
939
mi
from 91732
Spokane, WA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2102
mi
from 91732
Clarksburg, WV
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2102
mi
from 91732
Clarksburg, WV
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Research Site
7513
mi
from 91732
St Leonards,
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Research Site
7513
mi
from 91732
St Leonards,
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
4
mi
from 91732
Duarte, CA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
4
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
1729
mi
from 91732
Chicago, IL
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials